, par  Fabien ALMAIRAC, Philippe Paquis , popularité : 27%


1. Acker T, Plate KH. Hypoxia and hypoxia inducible factors (HIF) as important regulators of tumor physiology. Cancer Treat Res 2004 ;117:219-48.
2. Addeo R, Caraglia M, De Santi MS, Montella L, Abbruzzese A, Parlato C, et al. A new schedule of fotemustine in temozolomide-pretreated patients with relapsing glioblastoma. J Neurooncol 2011 ;102:417-24.
3. Affronti ML, Heery CR, Herndon JE, 2nd, Rich JN, Reardon DA, Desjardins A, et al. Overall survival of newly diagnosed glioblastoma patients receiving carmustine wafers followed by radiation and concurrent temozolomide plus rotational multiagent chemotherapy. Cancer 2009 ;115:3501-11.
4. Almairac F, Frenay M, Paquis P. [Genetic diseases and glioblastomas]. Neurochirurgie 2010 ;56:455-8.
5. Almairac F, Herbet G, Moritz-Gasser S, Duffau H. Parietal network underlying movement control : disturbances during subcortical electrostimulation. Neurosurg Rev 2014 ;37:513-6 ; discussion 16-7.
6. Ampil FL, Nanda A, Willis BK, Apple S. Treatment in patients with glioblastoma multiforme and poor performance status : is it worthwhile ? Radiat Med 1998 ;16:109-12.
7. Arvold ND, Reardon DA. Treatment options and outcomes for glioblastoma in the elderly patient. Clin Interv Aging 2014 ;9:357-67.
8. Bahr O, Hermisson M, Rona S, Rieger J, Nussbaum S, Kortvelyessy P, et al. Intravenous and oral levetiracetam in patients with a suspected primary brain tumor and symptomatic seizures undergoing neurosurgery : the HELLO trial. Acta Neurochir (Wien) 2012 ;154:229-35 ; discussion 35.
9. Baldi I, Huchet A, Bauchet L, Loiseau H. [Epidemiology of glioblastoma]. Neurochirurgie 2010 ;56:433-40.
10. Barone DG, Lawrie TA, Hart MG. Image guided surgery for the resection of brain tumours. Cochrane Database Syst Rev 2014 ;1:CD009685.
11. Batchelor TT, Betensky RA, Esposito JM, Pham LD, Dorfman MV, Piscatelli N, et al. Age-dependent prognostic effects of genetic alterations in glioblastoma. Clin Cancer Res 2004 ;10:228-33.
12. Bauchet L, Mathieu-Daude H, Fabbro-Peray P, Rigau V, Fabbro M, Chinot O, et al. Oncological patterns of care and outcome for 952 patients with newly diagnosed glioblastoma in 2004. Neuro Oncol 2010 ;12:725-35.
13. Bauchet L, Zouaoui S, Darlix A, Menjot de Champfleur N, Ferreira E, Fabbro M, et al. Assessment and treatment relevance in elderly glioblastoma patients. Neuro Oncol 2014 ;16:1459-68.
14. Bello L, Gallucci M, Fava M, Carrabba G, Giussani C, Acerbi F, et al. Intraoperative subcortical language tract mapping guides surgical removal of gliomas involving speech areas. Neurosurgery 2007 ;60:67-80 ; discussion 80-2.
15. Bello L, Riva M, Fava E, Ferpozzi V, Castellano A, Raneri F, et al. Tailoring neurophysiological strategies with clinical context enhances resection and safety and expands indications in gliomas involving motor pathways. Neuro Oncol 2014 ;16:1110-28.
16. Brandes AA, Rigon A, Zampieri P, Ermani M, Carollo C, Altavilla G, et al. Carboplatin and teniposide concurrent with radiotherapy in patients with glioblastoma multiforme : a phase II study. Cancer 1998 ;82:355-61.
17. Brandes AA, Tosoni A, Spagnolli F, Frezza G, Leonardi M, Calbucci F, et al. Disease progression or pseudoprogression after concomitant radiochemotherapy treatment : pitfalls in neurooncology. Neuro Oncol 2008 ;10:361-7.
18. Brandes AA, Franceschi E, Tosoni A, Benevento F, Scopece L, Mazzocchi V, et al. Temozolomide concomitant and adjuvant to radiotherapy in elderly patients with glioblastoma : correlation with MGMT promoter methylation status. Cancer 2009 ;115:3512-8.
19. Brell M, Ibanez J, Caral L, Ferrer E. Factors influencing surgical complications of intra-axial brain tumours. Acta Neurochir (Wien) 2000 ;142:739-50.
20. Brem H, Piantadosi S, Burger PC, Walker M, Selker R, Vick NA, et al. Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. The Polymer-brain Tumor Treatment Group. Lancet 1995 ;345:1008-12.
21. Brown M, Schrot R, Bauer K, Dodge J. Incidence of first primary central nervous system tumors in California, 2001-2005 : children, adolescents and teens. J Neurooncol 2009 ;94:263-73.
22. Burel-Vandenbos F, Turchi L, Benchetrit M, Fontas E, Pedeutour Z, Rigau V, et al. Cells with intense EGFR staining and a high nuclear to cytoplasmic ratio are specific for infiltrative glioma : a useful marker in neuropathological practice. Neuro Oncol 2013 ;15:1278-88.
23. Cairncross G, Berkey B, Shaw E, Jenkins R, Scheithauer B, Brachman D, et al. Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma : Intergroup Radiation Therapy Oncology Group Trial 9402. J Clin Oncol 2006 ;24:2707-14.
24. Carrabba G, Fava E, Giussani C, Acerbi F, Portaluri F, Songa V, et al. Cortical and subcortical motor mapping in rolandic and perirolandic glioma surgery : impact on postoperative morbidity and extent of resection. J Neurosurg Sci 2007 ;51:45-51.
25. Chaichana KL, Jusue-Torres I, Navarro-Ramirez R, Raza SM, Pascual-Gallego M, Ibrahim A, et al. Establishing percent resection and residual volume thresholds affecting survival and recurrence for patients with newly diagnosed intracranial glioblastoma. Neuro Oncol 2014 ;16:113-22.
26. Chamberlain MC, Johnston SK. Salvage therapy with single agent bevacizumab for recurrent glioblastoma. J Neurooncol 2010 ;96:259-69.
27. Chang SM, Parney IF, McDermott M, Barker FG, 2nd, Schmidt MH, Huang W, et al. Perioperative complications and neurological outcomes of first and second craniotomies among patients enrolled in the Glioma Outcome Project. J Neurosurg 2003 ;98:1175-81.
28. Chinot OL, Wick W, Mason W, Henriksson R, Saran F, Nishikawa R, et al. Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. N Engl J Med 2014 ;370:709-22.
29. Coureau G, Bouvier G, Lebailly P, Fabbro-Peray P, Gruber A, Leffondre K, et al. Mobile phone use and brain tumours in the CERENAT case-control study. Occup Environ Med 2014 ;71:514-22.
30. Curran WJ, Jr., Scott CB, Horton J, Nelson JS, Weinstein AS, Fischbach AJ, et al. Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials. J Natl Cancer Inst 1993 ;85:704-10.
31. Dammers R, Haitsma IK, Schouten JW, Kros JM, Avezaat CJ, Vincent AJ. Safety and efficacy of frameless and frame-based intracranial biopsy techniques. Acta Neurochir (Wien) 2008 ;150:23-9.
32. De Witt Hamer PC, Robles SG, Zwinderman AH, Duffau H, Berger MS. Impact of intraoperative stimulation brain mapping on glioma surgery outcome : a meta-analysis. J Clin Oncol 2012 ;30:2559-65.
33. Deltour I, Johansen C, Auvinen A, Feychting M, Klaeboe L, Schuz J. Time trends in brain tumor incidence rates in Denmark, Finland, Norway, and Sweden, 1974-2003. J Natl Cancer Inst 2009 ;101:1721-4.
34. Duffau H, Gatignol P, Mandonnet E, Peruzzi P, Tzourio-Mazoyer N, Capelle L. New insights into the anatomo-functional connectivity of the semantic system : a study using cortico-subcortical electrostimulations. Brain 2005 ;128:797-810.
35. Duffau H. The anatomo-functional connectivity of language revisited. New insights provided by electrostimulation and tractography. Neuropsychologia 2008 ;46:927-34.
36. Duffau H, Peggy Gatignol ST, Mandonnet E, Capelle L, Taillandier L. Intraoperative subcortical stimulation mapping of language pathways in a consecutive series of 115 patients with Grade II glioma in the left dominant hemisphere. J Neurosurg 2008 ;109:461-71.
37. Easaw JC, Mason WP, Perry J, Laperriere N, Eisenstat DD, Del Maestro R, et al. Canadian recommendations for the treatment of recurrent or progressive glioblastoma multiforme. Curr Oncol 2011 ;18:e126-36.
38. Esteller M, Herman JG. Generating mutations but providing chemosensitivity : the role of O6-methylguanine DNA methyltransferase in human cancer. Oncogene 2004 ;23:1-8.
39. Fabrini MG, Silvano G, Lolli I, Perrone F, Marsella A, Scotti V, et al. A multi-institutional phase II study on second-line Fotemustine chemotherapy in recurrent glioblastoma. J Neurooncol 2009 ;92:79-86.
40. Fareh M, Turchi L, Virolle V, Debruyne D, Almairac F, de-la-Forest Divonne S, et al. The miR 302-367 cluster drastically affects self-renewal and infiltration properties of glioma-initiating cells through CXCR4 repression and consequent disruption of the SHH-GLI-NANOG network. Cell Death Differ 2012 ;19:232-44.
41. Figarella-Branger D, Colin C, Tchoghandjian A, Baeza N, Bouvier C. [Glioblastomas : gliomagenesis, genetics, angiogenesis, and microenvironment]. Neurochirurgie 2010 ;56:441-8.
42. Fogh SE, Andrews DW, Glass J, Curran W, Glass C, Champ C, et al. Hypofractionated stereotactic radiation therapy : an effective therapy for recurrent high-grade gliomas. J Clin Oncol 2010 ;28:3048-53.
43. Fontaine D, Dormont D, Hasboun D, Clemenceau S, Valery C, Oppenheim C, et al. Magnetic resonance-guided stereotactic biopsies : results in 100 consecutive cases. Acta Neurochir (Wien) 2000 ;142:249-55 ; discussion 55-6.
44. Fontaine D, Vandenbos F, Lebrun C, Paquis V, Frenay M. [Diagnostic and prognostic values of 1p and 19q deletions in adult gliomas : critical review of the literature and implications in daily clinical practice]. Rev Neurol (Paris) 2008 ;164:595-604.
45. Fontaine D, Paquis P. [Glioblastoma : clinical, radiological and biological prognostic factors]. Neurochirurgie 2010 ;56:467-76.
46. Friedman HS, Prados MD, Wen PY, Mikkelsen T, Schiff D, Abrey LE, et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 2009 ;27:4733-40.
47. Gallego Perez-Larraya J, Lahutte M, Petrirena G, Reyes-Botero G, Gonzalez-Aguilar A, Houillier C, et al. Response assessment in recurrent glioblastoma treated with irinotecan-bevacizumab : comparative analysis of the Macdonald, RECIST, RANO, and RECIST + F criteria. Neuro Oncol 2012 ;14:667-73.
48. Gerber NK, Goenka A, Turcan S, Reyngold M, Makarov V, Kannan K, et al. Transcriptional diversity of long-term glioblastoma survivors. Neuro Oncol 2014 ;16:1186-95.
49. Gilbert MR, Dignam JJ, Armstrong TS, Wefel JS, Blumenthal DT, Vogelbaum MA, et al. A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med 2014 ;370:699-708.
50. Gras-Combe G, Moritz-Gasser S, Herbet G, Duffau H. Intraoperative subcortical electrical mapping of optic radiations in awake surgery for glioma involving visual pathways. J Neurosurg 2012 ;117:466-73.
51. Graus F, Bruna J, Pardo J, Escudero D, Vilas D, Barcelo I, et al. Patterns of care and outcome for patients with glioblastoma diagnosed during 2008-2010 in Spain. Neuro Oncol 2013 ;15:797-805.
52. Grosu AL, Weber WA, Franz M, Stark S, Piert M, Thamm R, et al. Reirradiation of recurrent high-grade gliomas using amino acid PET (SPECT)/CT/MRI image fusion to determine gross tumor volume for stereotactic fractionated radiotherapy. Int J Radiat Oncol Biol Phys 2005 ;63:511-9.
53. Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 2005 ;352:997-1003.
54. Herbet G, Lafargue G, Bonnetblanc F, Moritz-Gasser S, Menjot de Champfleur N, Duffau H. Inferring a dual-stream model of mentalizing from associative white matter fibres disconnection. Brain 2014 ;137:944-59.
55. Hochberg FH, Pruitt A. Assumptions in the radiotherapy of glioblastoma. Neurology 1980 ;30:907-11.
56. Holdhoff M, Chamberlain MC. Controversies in the treatment of elderly patients with newly diagnosed glioblastoma. J Natl Compr Canc Netw 2013 ;11:1165-72 ; quiz 73.
57. Houillier C, Lejeune J, Benouaich-Amiel A, Laigle-Donadey F, Criniere E, Mokhtari K, et al. Prognostic impact of molecular markers in a series of 220 primary glioblastomas. Cancer 2006 ;106:2218-23.
58. Huang SC, Chen CR, Lavine JE, Taylor SF, Newbury RO, Pham TT, et al. Genetic heterogeneity in familial juvenile polyposis. Cancer Res 2000 ;60:6882-5.
59. Johannesen TB, Angell-Andersen E, Tretli S, Langmark F, Lote K. Trends in incidence of brain and central nervous system tumors in Norway, 1970-1999. Neuroepidemiology 2004 ;23:101-9.
60. Johnson DR, O’Neill BP. Glioblastoma survival in the United States before and during the temozolomide era. J Neurooncol 2012 ;107:359-64.
61. Johnson DR, Sawyer AM, Meyers CA, O’Neill BP, Wefel JS. Early measures of cognitive function predict survival in patients with newly diagnosed glioblastoma. Neuro Oncol 2012 ;14:808-16.
62. Kelly PJ, Daumas-Duport C, Kispert DB, Kall BA, Scheithauer BW, Illig JJ. Imaging-based stereotaxic serial biopsies in untreated intracranial glial neoplasms. J Neurosurg 1987 ;66:865-74.
63. Kreisl TN, Kim L, Moore K, Duic P, Royce C, Stroud I, et al. Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol 2009 ;27:740-5.
64. Krex D, Klink B, Hartmann C, von Deimling A, Pietsch T, Simon M, et al. Long-term survival with glioblastoma multiforme. Brain 2007 ;130:2596-606.
65. Lacroix M, Abi-Said D, Fourney DR, Gokaslan ZL, Shi W, DeMonte F, et al. A multivariate analysis of 416 patients with glioblastoma multiforme : prognosis, extent of resection, and survival. J Neurosurg 2001 ;95:190-8.
66. Lai A, Tran A, Nghiemphu PL, Pope WB, Solis OE, Selch M, et al. Phase II study of bevacizumab plus temozolomide during and after radiation therapy for patients with newly diagnosed glioblastoma multiforme. J Clin Oncol 2011 ;29:142-8.
67. Laperriere N, Zuraw L, Cairncross G. Radiotherapy for newly diagnosed malignant glioma in adults : a systematic review. Radiother Oncol 2002 ;64:259-73.
68. Levin VA, Bidaut L, Hou P, Kumar AJ, Wefel JS, Bekele BN, et al. Randomized double-blind placebo-controlled trial of bevacizumab therapy for radiation necrosis of the central nervous system. Int J Radiat Oncol Biol Phys 2011 ;79:1487-95.
69. Li J, Wang M, Won M, Shaw EG, Coughlin C, Curran WJ, Jr., et al. Validation and simplification of the Radiation Therapy Oncology Group recursive partitioning analysis classification for glioblastoma. Int J Radiat Oncol Biol Phys 2011 ;81:623-30.
70. Linos E, Raine T, Alonso A, Michaud D. Atopy and risk of brain tumors : a meta-analysis. J Natl Cancer Inst 2007 ;99:1544-50.
71. Lombardi G, Della Puppa A, Zustovich F, Pambuku A, Farina P, Fiduccia P, et al. The combination of carmustine wafers and fotemustine in recurrent glioblastoma patients : a monoinstitutional experience. Biomed Res Int 2014 ;2014:678191.
72. Lonjon N, Bauchet L, Duffau H, Fabbro-Peray P, Segnarbieux F, Paquis P, et al. [Second surgery for glioblastoma. A 4-year retrospective study conducted in both the Montpellier and Nice Departments of Neurosurgery. A literature review]. Neurochirurgie 2010 ;56:36-42.
73. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 2007 ;114:97-109.
74. Malmstrom A, Gronberg BH, Marosi C, Stupp R, Frappaz D, Schultz H, et al. Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma : the Nordic randomised, phase 3 trial. Lancet Oncol 2012 ;13:916-26.
75. Matsukado Y, Maccarty CS, Kernohan JW. The growth of glioblastoma multiforme (astrocytomas, grades 3 and 4) in neurosurgical practice. J Neurosurg 1961 ;18:636-44.
76. McGirt MJ, Than KD, Weingart JD, Chaichana KL, Attenello FJ, Olivi A, et al. Gliadel (BCNU) wafer plus concomitant temozolomide therapy after primary resection of glioblastoma multiforme. J Neurosurg 2009 ;110:583-8.
77. McKinley BP, Michalek AM, Fenstermaker RA, Plunkett RJ. The impact of age and sex on the incidence of glial tumors in New York state from 1976 to 1995. J Neurosurg 2000 ;93:932-9.
78. McPherson CM, Warnick RE. Results of contemporary surgical management of radiation necrosis using frameless stereotaxis and intraoperative magnetic resonance imaging. J Neurooncol 2004 ;68:41-7.
79. Menei P, Capelle L, Guyotat J, Fuentes S, Assaker R, Bataille B, et al. Local and sustained delivery of 5-fluorouracil from biodegradable microspheres for the radiosensitization of malignant glioma : a randomized phase II trial. Neurosurgery 2005 ;56:242-8 ; discussion 42-8.
80. Menei P, Metellus P. [Surgical treatment of glioblastomas]. Neurochirurgie 2010 ;56:477-82.
81. Menei P, Metellus P, Parot-Schinkel E, Loiseau H, Capelle L, Jacquet G, et al. Biodegradable carmustine wafers (Gliadel) alone or in combination with chemoradiotherapy : the French experience. Ann Surg Oncol 2010 ;17:1740-6.
82. Minniti G, De Sanctis V, Muni R, Filippone F, Bozzao A, Valeriani M, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma in elderly patients. J Neurooncol 2008 ;88:97-103.
83. Mirimanoff RO, Gorlia T, Mason W, Van den Bent MJ, Kortmann RD, Fisher B, et al. Radiotherapy and temozolomide for newly diagnosed glioblastoma : recursive partitioning analysis of the EORTC 26981/22981-NCIC CE3 phase III randomized trial. J Clin Oncol 2006 ;24:2563-9.
84. Nazzaro JM, Neuwelt EA. The role of surgery in the management of supratentorial intermediate and high-grade astrocytomas in adults. J Neurosurg 1990 ;73:331-44.
85. Nobusawa S, Watanabe T, Kleihues P, Ohgaki H. IDH1 mutations as molecular signature and predictive factor of secondary glioblastomas. Clin Cancer Res 2009 ;15:6002-7.
86. Ohgaki H, Kleihues P. Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas. J Neuropathol Exp Neurol 2005 ;64:479-89.
87. Ohgaki H, Kleihues P. Genetic pathways to primary and secondary glioblastoma. Am J Pathol 2007 ;170:1445-53.
88. Oppenlander ME, Wolf AB, Snyder LA, Bina R, Wilson JR, Coons SW, et al. An extent of resection threshold for recurrent glioblastoma and its risk for neurological morbidity. J Neurosurg 2014 ;120:846-53.
89. Orringer D, Lau D, Khatri S, Zamora-Berridi GJ, Zhang K, Wu C, et al. Extent of resection in patients with glioblastoma : limiting factors, perception of resectability, and effect on survival. J Neurosurg 2012 ;117:851-9.
90. Ostrom QT, Gittleman H, Farah P, Ondracek A, Chen Y, Wolinsky Y, et al. CBTRUS statistical report : Primary brain and central nervous system tumors diagnosed in the United States in 2006-2010. Neuro Oncol 2013 ;15 Suppl 2:ii1-56.
91. Pallud J, Taillandier L, Capelle L, Fontaine D, Peyre M, Ducray F, et al. Quantitative morphological magnetic resonance imaging follow-up of low-grade glioma : a plea for systematic measurement of growth rates. Neurosurgery 2012 ;71:729-39 ; discussion 39-40.
92. Paquis P, Menei P. [Conclusions : glioblastomas. standards, options, recommendations]. Neurochirurgie 2010 ;56:503-7.
93. Perry JR, Belanger K, Mason WP, Fulton D, Kavan P, Easaw J, et al. Phase II trial of continuous dose-intense temozolomide in recurrent malignant glioma : RESCUE study. J Clin Oncol 2010 ;28:2051-7.
94. Piette C, Munaut C, Foidart JM, Deprez M. Treating gliomas with glucocorticoids : from bedside to bench. Acta Neuropathol 2006 ;112:651-64.
95. Prayson RA, Agamanolis DP, Cohen ML, Estes ML, Kleinschmidt-DeMasters BK, Abdul-Karim F, et al. Interobserver reproducibility among neuropathologists and surgical pathologists in fibrillary astrocytoma grading. J Neurol Sci 2000 ;175:33-9.
96. Pulman J, Greenhalgh J, Marson AG. Antiepileptic drugs as prophylaxis for post-craniotomy seizures. Cochrane Database Syst Rev 2013 ;2:CD007286.
97. Quick J, Gessler F, Dutzmann S, Hattingen E, Harter PN, Weise LM, et al. Benefit of tumor resection for recurrent glioblastoma. J Neurooncol 2014 ;117:365-72.
98. Quillien V, Lavenu A, Karayan-Tapon L, Carpentier C, Labussiere M, Lesimple T, et al. Comparative assessment of 5 methods (methylation-specific polymerase chain reaction, MethyLight, pyrosequencing, methylation-sensitive high-resolution melting, and immunohistochemistry) to analyze O6-methylguanine-DNA-methyltranferase in a series of 100 glioblastoma patients. Cancer 2012 ;118:4201-11.
99. Raizer JJ, Grimm S, Chamberlain MC, Nicholas MK, Chandler JP, Muro K, et al. A phase 2 trial of single-agent bevacizumab given in an every-3-week schedule for patients with recurrent high-grade gliomas. Cancer 2010 ;116:5297-305.
100. Rasheed A, Herndon JE, Stenzel TT, Raetz JG, Kendelhardt J, Friedman HS, et al. Molecular markers of prognosis in astrocytic tumors. Cancer 2002 ;94:2688-97.
101. Reardon DA. Treatment of elderly patients with glioblastoma. Lancet Oncol 2012 ;13:656-7.
102. Ricard D, Idbaih A, Ducray F, Lahutte M, Hoang-Xuan K, Delattre JY. Primary brain tumours in adults. Lancet 2012 ;379:1984-96.
103. Ruben JD, Dally M, Bailey M, Smith R, McLean CA, Fedele P. Cerebral radiation necrosis : incidence, outcomes, and risk factors with emphasis on radiation parameters and chemotherapy. Int J Radiat Oncol Biol Phys 2006 ;65:499-508.
104. Ruder AM, Carreon T, Butler MA, Calvert GM, Davis-King KE, Waters MA, et al. Exposure to farm crops, livestock, and farm tasks and risk of glioma : the Upper Midwest Health Study. Am J Epidemiol 2009 ;169:1479-91.
105. Sacko O, Lauwers-Cances V, Brauge D, Sesay M, Brenner A, Roux FE. Awake craniotomy vs surgery under general anesthesia for resection of supratentorial lesions. Neurosurgery 2011 ;68:1192-8 ; discussion 98-9.
106. Sanai N, Berger MS. Glioma extent of resection and its impact on patient outcome. Neurosurgery 2008 ;62:753-64 ; discussion 264-6.
107. Sanai N, Mirzadeh Z, Berger MS. Functional outcome after language mapping for glioma resection. N Engl J Med 2008 ;358:18-27.
108. Sanai N, Polley MY, McDermott MW, Parsa AT, Berger MS. An extent of resection threshold for newly diagnosed glioblastomas. J Neurosurg 2011 ;115:3-8.
109. Sanghera P, Perry J, Sahgal A, Symons S, Aviv R, Morrison M, et al. Pseudoprogression following chemoradiotherapy for glioblastoma multiforme. Can J Neurol Sci 2010 ;37:36-42.
110. Sanson M, Marie Y, Paris S, Idbaih A, Laffaire J, Ducray F, et al. Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas. J Clin Oncol 2009 ;27:4150-4.
111. Sawaya R, Hammoud M, Schoppa D, Hess KR, Wu SZ, Shi WM, et al. Neurosurgical outcomes in a modern series of 400 craniotomies for treatment of parenchymal tumors. Neurosurgery 1998 ;42:1044-55 ; discussion 55-6.
112. Schmidt MC, Antweiler S, Urban N, Mueller W, Kuklik A, Meyer-Puttlitz B, et al. Impact of genotype and morphology on the prognosis of glioblastoma. J Neuropathol Exp Neurol 2002 ;61:321-8.
113. Schucht P, Beck J, Abu-Isa J, Andereggen L, Murek M, Seidel K, et al. Gross total resection rates in contemporary glioblastoma surgery : results of an institutional protocol combining 5-aminolevulinic acid intraoperative fluorescence imaging and brain mapping. Neurosurgery 2012 ;71:927-35 ; discussion 35-6.
114. Schucht P, Knittel S, Slotboom J, Seidel K, Murek M, Jilch A, et al. 5-ALA complete resections go beyond MR contrast enhancement : shift corrected volumetric analysis of the extent of resection in surgery for glioblastoma. Acta Neurochir (Wien) 2014 ;156:305-12 ; discussion 12.
115. Scott JG, Bauchet L, Fraum TJ, Nayak L, Cooper AR, Chao ST, et al. Recursive partitioning analysis of prognostic factors for glioblastoma patients aged 70 years or older. Cancer 2012 ;118:5595-600.
116. Senft C, Bink A, Franz K, Vatter H, Gasser T, Seifert V. Intraoperative MRI guidance and extent of resection in glioma surgery : a randomised, controlled trial. Lancet Oncol 2011 ;12:997-1003.
117. Shinojima N, Tada K, Shiraishi S, Kamiryo T, Kochi M, Nakamura H, et al. Prognostic value of epidermal growth factor receptor in patients with glioblastoma multiforme. Cancer Res 2003 ;63:6962-70.
118. Shooman D, Belli A, Grundy PL. Image-guided frameless stereotactic biopsy without intraoperative neuropathological examination. J Neurosurg 2010 ;113:170-8.
119. Sijben AE, McIntyre JB, Roldan GB, Easaw JC, Yan E, Forsyth PA, et al. Toxicity from chemoradiotherapy in older patients with glioblastoma multiforme. J Neurooncol 2008 ;89:97-103.
120. Singh SK, Hawkins C, Clarke ID, Squire JA, Bayani J, Hide T, et al. Identification of human brain tumour initiating cells. Nature 2004 ;432:396-401.
121. Soffietti R, Baumert BG, Bello L, von Deimling A, Duffau H, Frenay M, et al. Guidelines on management of low-grade gliomas : report of an EFNS-EANO Task Force. Eur J Neurol 2010 ;17:1124-33.
122. Soffietti R, Trevisan E, Bertero L, Cassoni P, Morra I, Fabrini MG, et al. Bevacizumab and fotemustine for recurrent glioblastoma : a phase II study of AINO (Italian Association of Neuro-Oncology). J Neurooncol 2014 ;116:533-41.
123. Stewart LA. Chemotherapy in adult high-grade glioma : a systematic review and meta-analysis of individual patient data from 12 randomised trials. Lancet 2002 ;359:1011-8.
124. Stummer W, Pichlmeier U, Meinel T, Wiestler OD, Zanella F, Reulen HJ. Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma : a randomised controlled multicentre phase III trial. Lancet Oncol 2006 ;7:392-401.
125. Stummer W, Reulen HJ, Meinel T, Pichlmeier U, Schumacher W, Tonn JC, et al. Extent of resection and survival in glioblastoma multiforme : identification of and adjustment for bias. Neurosurgery 2008 ;62:564-76 ; discussion 64-76.
126. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005 ;352:987-96.
127. Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study : 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 2009 ;10:459-66.
128. Szelenyi A, Senft C, Jardan M, Forster MT, Franz K, Seifert V, et al. Intra-operative subcortical electrical stimulation : a comparison of two methods. Clin Neurophysiol 2011 ;122:1470-5.
129. Taal W, Brandsma D, de Bruin HG, Bromberg JE, Swaak-Kragten AT, Smitt PA, et al. Incidence of early pseudo-progression in a cohort of malignant glioma patients treated with chemoirradiation with temozolomide. Cancer 2008 ;113:405-10.
130. Telera S, Fabi A, Pace A, Vidiri A, Anelli V, Carapella CM, et al. Radionecrosis induced by stereotactic radiosurgery of brain metastases : results of surgery and outcome of disease. J Neurooncol 2013 ;113:313-25.
131. Thiebaut de Schotten M, Urbanski M, Duffau H, Volle E, Levy R, Dubois B, et al. Direct evidence for a parietal-frontal pathway subserving spatial awareness in humans. Science 2005 ;309:2226-8.
132. Tye K, Engelhard HH, Slavin KV, Nicholas MK, Chmura SJ, Kwok Y, et al. An analysis of radiation necrosis of the central nervous system treated with bevacizumab. J Neurooncol 2014 ;117:321-7.
133. Unsgaard G, Gronningsaeter A, Ommedal S, Nagelhus Hernes TA. Brain operations guided by real-time two-dimensional ultrasound : new possibilities as a result of improved image quality. Neurosurgery 2002 ;51:402-11 ; discussion 11-2.
134. Verhaak RG, Hoadley KA, Purdom E, Wang V, Qi Y, Wilkerson MD, et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 2010 ;17:98-110.
135. Vorster SJ, Barnett GH. A proposed preoperative grading scheme to assess risk for surgical resection of primary and secondary intraaxial supratentorial brain tumors. Neurosurg Focus 1998 ;4:e2.
136. Vredenburgh JJ, Desjardins A, Herndon JE, 2nd, Marcello J, Reardon DA, Quinn JA, et al. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol 2007 ;25:4722-9.
137. Vuorinen V, Hinkka S, Farkkila M, Jaaskelainen J. Debulking or biopsy of malignant glioma in elderly people - a randomised study. Acta Neurochir (Wien) 2003 ;145:5-10.
138. Weller M, Gorlia T, Cairncross JG, van den Bent MJ, Mason W, Belanger K, et al. Prolonged survival with valproic acid use in the EORTC/NCIC temozolomide trial for glioblastoma. Neurology 2011 ;77:1156-64.
139. Weller M, van den Bent M, Hopkins K, Tonn JC, Stupp R, Falini A, et al. EANO guideline for the diagnosis and treatment of anaplastic gliomas and glioblastoma. Lancet Oncol 2014 ;15:e395-403.
140. Wen PY, Macdonald DR, Reardon DA, Cloughesy TF, Sorensen AG, Galanis E, et al. Updated response assessment criteria for high-grade gliomas : response assessment in neuro-oncology working group. J Clin Oncol 2010 ;28:1963-72.
141. Westphal M, Hilt DC, Bortey E, Delavault P, Olivares R, Warnke PC, et al. A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma. Neuro Oncol 2003 ;5:79-88.
142. Wick A, Felsberg J, Steinbach JP, Herrlinger U, Platten M, Blaschke B, et al. Efficacy and tolerability of temozolomide in an alternating weekly regimen in patients with recurrent glioma. J Clin Oncol 2007 ;25:3357-61.
143. Wick W, Platten M, Meisner C, Felsberg J, Tabatabai G, Simon M, et al. Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly : the NOA-08 randomised, phase 3 trial. Lancet Oncol 2012 ;13:707-15.
144. Wick W, Weller M, van den Bent M, Sanson M, Weiler M, von Deimling A, et al. MGMT testing—the challenges for biomarker-based glioma treatment. Nat Rev Neurol 2014 ;10:372-85.
145. Willems PW, Taphoorn MJ, Burger H, Berkelbach van der Sprenkel JW, Tulleken CA. Effectiveness of neuronavigation in resecting solitary intracerebral contrast-enhancing tumors : a randomized controlled trial. J Neurosurg 2006 ;104:360-8.
146. Wohrer A, Waldhor T, Heinzl H, Hackl M, Feichtinger J, Gruber-Mosenbacher U, et al. The Austrian Brain Tumour Registry : a cooperative way to establish a population-based brain tumour registry. J Neurooncol 2009 ;95:401-11.
147. Woodworth GF, McGirt MJ, Samdani A, Garonzik I, Olivi A, Weingart JD. Frameless image-guided stereotactic brain biopsy procedure : diagnostic yield, surgical morbidity, and comparison with the frame-based technique. J Neurosurg 2006 ;104:233-7.
148. Yan H, Parsons DW, Jin G, McLendon R, Rasheed BA, Yuan W, et al. IDH1 and IDH2 mutations in gliomas. N Engl J Med 2009 ;360:765-73.
149. Yoshii Y. Pathological review of late cerebral radionecrosis. Brain Tumor Pathol 2008 ;25:51-8.
150. Young GS. Advanced MRI of adult brain tumors. Neurol Clin 2007 ;25:947-73, viii.
151. Yuan Y, Xiang W, Qing M, Yanhui L, Jiewen L, Yunhe M. Survival analysis for valproic acid use in adult glioblastoma multiforme : A meta-analysis of individual patient data and a systematic review. Seizure 2014.
152. Zouaoui S, Rigau V, Mathieu-Daude H, Darlix A, Bessaoud F, Fabbro-Peray P, et al. [French brain tumor database : general results on 40,000 cases, main current applications and future prospects]. Neurochirurgie 2012 ;58:4-13.